NIRRIN TECHNOLOGIES INC
Making Medicines Easier to Make
Billerica, United States · Founded 2024 · $15.2M raised
- Headquarters
- Billerica, Massachusetts
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- nirrin.tech
- Total Funding
- $15.2M
- Last Round
- $6.7M Venture RoundJun 2026
- Rounds
- 2
About
Nirrin Technologies develops high-precision tunable laser spectroscopy (HPTLS) analytical systems for biopharma biomanufacturing. Their Atlas system provides at-line, in-line, and in-situ process analytical solutions for complex biologics and advanced therapies, enabling rapid measurement of product titer and buffer/excipient concentrations. The NIH awarded Nirrin a $2M grant to further develop its optical spectroscopy technique for rapid characterization of complex biomanufacturing processes.
Summary
NIRRIN TECHNOLOGIES INC is a Biotech company based in Billerica, United States, founded in 2024. It has raised $15.2M in total across 2 rounds, most recently a $6.7M Venture Round round in Jun 2026. Investors include Anzu Partners and BioTools Innovator.
Tech & App Stack
2 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jun 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.

Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
BridgeBio makes targeted treatments for genetic diseases.